

PRESS RELEASE
March 27, 2003



FOR IMMEDIATE RELEASE

CONTACT Daniel Bickford
Director of Marketing and Sales
T 425/576-3229
E dbickford@confirma.com

Confirma Names Max Lyon President and Chief Executive Officer

Kirkland, WA – March 27, 2003 – Confirma, Inc., a medical device company focused on developing computer-aided-detection (CAD) systems for medical imaging applications, today announced Max Lyon has been appointed President and Chief Executive Officer. Lyon brings more than twenty years of experience in founding and managing medical technology companies.

“Max is joining the company at an exciting time, during its first commercial product launch and as the company realizes its first sales,” said William Link, PhD, Confirma Board Member and Managing Director of Versant Ventures. “His experience in leadership roles in the medical technology industry will be a great asset to Confirma.”

Lyon was most recently the President and CEO of LifeSpex, Inc., a development-stage company applying light-based technologies to early cancer detection. From 1998 to 2000, he was a founder, Director and CEO of NexCura (formerly Cancerfacts.com), a web-based cancer management company. From 1988 to 1998, Lyon served as CEO and a Director of Bard Diagnostics (formerly Bainbridge Sciences), a wholly owned subsidiary of C.R. Bard. Additionally, he has held executive positions at BioControl Systems and Genetic Systems Corp. Lyon holds a MBA from City University and a BA from Cornell University.

“I am excited to be involved in the introduction of a new technology to the medical imaging market,” said Lyon. “Confirma’s first product, CADstream™, provides a unique opportunity to

-- more --

Confirma Names Max Lyon President & CEO
Page 2

improve the way that radiologists interpret magnetic resonance imaging (MRI) studies of the breast. This is especially important as the incidence of breast cancer in the U.S. continues to rise," he continued. "I look forward to working with the team to continue building the company and its products."

CADstream is the first CAD system for analysis of breast MRI studies. CADstream automates breast MR image processing functions and registers study data to correct for patient movement. The result is higher quality, standardized imaging studies and improved breast MRI economics.

MRI is rapidly gaining momentum as a highly accurate breast imaging method and the number of breast MRI studies has been increasing steadily. Since 1999, there has been a 40 percent increase in the number of these studies performed each year. Breast MRI is primarily used for screening high-risk breast cancer patients, determining extent of disease (staging) and monitoring response to therapy in breast cancer patients.

About Confirma, Inc.

Confirma, Inc. develops and markets computer-aided-detection (CAD) systems for MRI analysis. Confirma's first product, CADstream, provides higher quality imaging studies, lower costs for radiology practices and improved communication tools for physicians and patients. In its initial application, CADstream is being used to assist in the analysis of breast MRI; the company plans future applications in other MRI areas. For more information, visit www.confirma.com.

###